Daniel Vázquez-Vicente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Vázquez-Vicente has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Luis Chiva
Cancer Center Universidad de Navarra, Madrid, Spain
10 shared publications - Enrique Chacon
Department of Gynecologic Oncology, Universidad de Navarra, Pamplona, Spain
6 shared publications - Felix Boria
Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Spain
6 shared publications - Nabil Manzour
Department of Gynecology, Clínica Universidad de Navarra, Pamplona, Spain
5 shared publications Teresa Castellanos
48Department of Gynecology, Clinica Universitaria de Navarra, Madrid, Spain
5 shared publications- Juan Luis Alcázar
Department of Obstetrics and Gynecology Hospital Quironsalud Málaga Spain
3 shared publications
Latest Publications
- 15 February 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (4) , 101694
Horseshoe kidney
- 15 February 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (4) , 101694
Horseshoe kidney
- 13 March 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (6) , 942-945
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)
Background Currently, a lively debate exists within the scientific community regarding the most suitable procedure for treating stages IIIB–IVB carcinoma of the ovary, fallopian tubes, and peritoneum. The options under most consideration are primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval cytoreductive surgery. Primary Objective To compare overall survival at 5 years in patients who underwent primary cytoreductive surgery versus neoadjuvant chemotherapy and interval cytoreductive surgery for stage IIIB–IVB ovarian cancer Study Hypothesis The treatment with primary cytoreductive surgery results in superior patient survival compared with neoadjuvant chemotherapy followed by interval cytoreductive surgery. Trial Design This is a multicenter, retrospective cohort observational study. Data will be collected from patients undergoing surgery in hospitals worldwide. Two arms will be compared: primary cytoreductive surgery and neoadjuvant chemotherapy followed by interval cytoreductive surgery. Major Inclusion/Exclusion Criteria Patients must have suspected or histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stages IIIB–IVB ovarian, peritoneal, or fallopian tube cancers. They must have undergone primary surgery or first course of neoadjuvant chemotherapy between January 1, 2018 and December 31, 2019. Based on all available information before the surgery (primary or interval), the patient must have been considered completely resectable. Primary Endpoint Overall survival at 5 years from the first treatment (chemotherapy in the case of neoadjuvant chemotherapy and cytoreduction in the case of primary cytoreductive surgery). Sample Size An estimated total of 5000 patients will be enrolled in the study. Estimated Dates for Completing Accrual and Presenting Results March 2025 Trial Registration NCT06223763
- 13 March 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (6) , 942-945
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)
Background Currently, a lively debate exists within the scientific community regarding the most suitable procedure for treating stages IIIB–IVB carcinoma of the ovary, fallopian tubes, and peritoneum. The options under most consideration are primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval cytoreductive surgery. Primary Objective To compare overall survival at 5 years in patients who underwent primary cytoreductive surgery versus neoadjuvant chemotherapy and interval cytoreductive surgery for stage IIIB–IVB ovarian cancer Study Hypothesis The treatment with primary cytoreductive surgery results in superior patient survival compared with neoadjuvant chemotherapy followed by interval cytoreductive surgery. Trial Design This is a multicenter, retrospective cohort observational study. Data will be collected from patients undergoing surgery in hospitals worldwide. Two arms will be compared: primary cytoreductive surgery and neoadjuvant chemotherapy followed by interval cytoreductive surgery. Major Inclusion/Exclusion Criteria Patients must have suspected or histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stages IIIB–IVB ovarian, peritoneal, or fallopian tube cancers. They must have undergone primary surgery or first course of neoadjuvant chemotherapy between January 1, 2018 and December 31, 2019. Based on all available information before the surgery (primary or interval), the patient must have been considered completely resectable. Primary Endpoint Overall survival at 5 years from the first treatment (chemotherapy in the case of neoadjuvant chemotherapy and cytoreduction in the case of primary cytoreductive surgery). Sample Size An estimated total of 5000 patients will be enrolled in the study. Estimated Dates for Completing Accrual and Presenting Results March 2025 Trial Registration NCT06223763
- Open Access
- 13 April 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (6) , 951-956
Ultrasound examination, MRI, or ROMA for discriminating between inconclusive adnexal masses as determined by IOTA Simple Rules: a prospective study
Objective To determine the best second-step approach for discriminating benign from malignant adnexal masses classified as inconclusive by International Ovarian Tumour Analysis Simple Rules (IOTA-SR). Methods Single-center prospective study comprising a consecutive series of patients diagnosed as having an adnexal mass classified as inconclusive according to IOTA-SR. All women underwent Risk of Ovarian Malignancy Algorithm (ROMA) analysis, MRI interpreted by a radiologist, and ultrasound examination by a gynecological sonologist. Cases were clinically managed according to the result of the ultrasound expert examination by either serial follow-up for at least 1 year or surgery. Reference standard was histology (patient was submitted to surgery if any of the tests was suspicious) or follow-up (masses with no signs of malignancy after 12 months were considered benign). Diagnostic performance of all three approaches was calculated and compared. Direct cost analysis of the test used was also performed. Results Eighty-two adnexal masses in 80 women (median age 47.6 years, range 16 to 73 years) were included. Seventeen patients (17 masses) were managed expectantly (none had diagnosis of ovarian cancer after at least 12 months of follow-up) and 63 patients (65 masses) underwent surgery and tumor removal (40 benign and 25 malignant tumors). Sensitivity and specificity for ultrasound, MRI, and ROMA were 96% and 93%, 100% and 81%, and 24% and 93%, respectively. The specificity of ultrasound was better than that for MRI (p=0.021), and the sensitivity of ultrasound was better than that for ROMA (pConclusion In this study, ultrasound examination was the best second-step approach in inconclusive adnexal masses as determined by IOTA-SR, but the findings require confirmation in multicenter prospective trials.
- 13 April 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (6) , 951-956
Open AccessUltrasound examination, MRI, or ROMA for discriminating between inconclusive adnexal masses as determined by IOTA Simple Rules: a prospective study
Objective To determine the best second-step approach for discriminating benign from malignant adnexal masses classified as inconclusive by International Ovarian Tumour Analysis Simple Rules (IOTA-SR). Methods Single-center prospective study comprising a consecutive series of patients diagnosed as having an adnexal mass classified as inconclusive according to IOTA-SR. All women underwent Risk of Ovarian Malignancy Algorithm (ROMA) analysis, MRI interpreted by a radiologist, and ultrasound examination by a gynecological sonologist. Cases were clinically managed according to the result of the ultrasound expert examination by either serial follow-up for at least 1 year or surgery. Reference standard was histology (patient was submitted to surgery if any of the tests was suspicious) or follow-up (masses with no signs of malignancy after 12 months were considered benign). Diagnostic performance of all three approaches was calculated and compared. Direct cost analysis of the test used was also performed. Results Eighty-two adnexal masses in 80 women (median age 47.6 years, range 16 to 73 years) were included. Seventeen patients (17 masses) were managed expectantly (none had diagnosis of ovarian cancer after at least 12 months of follow-up) and 63 patients (65 masses) underwent surgery and tumor removal (40 benign and 25 malignant tumors). Sensitivity and specificity for ultrasound, MRI, and ROMA were 96% and 93%, 100% and 81%, and 24% and 93%, respectively. The specificity of ultrasound was better than that for MRI (p=0.021), and the sensitivity of ultrasound was better than that for ROMA (pConclusion In this study, ultrasound examination was the best second-step approach in inconclusive adnexal masses as determined by IOTA-SR, but the findings require confirmation in multicenter prospective trials.
- Open Access
- 1 February 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (7) , 1154-1155
Conservative endoscopic management of colorectal anastomotic leak in advanced ovarian cancer
- 1 February 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (7) , 1154-1155
Open AccessConservative endoscopic management of colorectal anastomotic leak in advanced ovarian cancer
- 1 September 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (9) , 1212-1219
Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators
Introduction Comprehensive updated information on cervical cancer surgical treatment in Europe is scarce. Objective To evaluate baseline characteristics of women with early cervical cancer and to analyze the outcomes of the ESGO quality indicators after radical hysterectomy in the SUCCOR database. Methods The SUCCOR database consisted of 1272 patients who underwent radical hysterectomy for stage IB1 cervical cancer (FIGO 2009) between January 2013 and December 2014. After exclusion criteria, the final sample included 1156 patients. This study first described the clinical, surgical, pathological, and follow-up variables of this population and then analyzed the outcomes (disease-free survival and overall survival) after radical hysterectomy. Surgical-related ESGO quality indicators were assessed and the accomplishment of the stated recommendations was verified. Results The mean age of the patients was 47.1 years (SD 10.8), with a mean body mass index of 25.4 kg/m2 (SD 4.9). A total of 423 (36.6%) patients had a previous cone biopsy. Tumor size (clinical examination) Conclusions In this European cohort, the rate of adjuvant therapy after radical hysterectomy is higher than for most similar patients reported in the literature. The majority of centers were already following the European recommendations even 5 years prior to the ESGO quality indicator implementations.
- 1 September 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (9) , 1212-1219
Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators
Introduction Comprehensive updated information on cervical cancer surgical treatment in Europe is scarce. Objective To evaluate baseline characteristics of women with early cervical cancer and to analyze the outcomes of the ESGO quality indicators after radical hysterectomy in the SUCCOR database. Methods The SUCCOR database consisted of 1272 patients who underwent radical hysterectomy for stage IB1 cervical cancer (FIGO 2009) between January 2013 and December 2014. After exclusion criteria, the final sample included 1156 patients. This study first described the clinical, surgical, pathological, and follow-up variables of this population and then analyzed the outcomes (disease-free survival and overall survival) after radical hysterectomy. Surgical-related ESGO quality indicators were assessed and the accomplishment of the stated recommendations was verified. Results The mean age of the patients was 47.1 years (SD 10.8), with a mean body mass index of 25.4 kg/m2 (SD 4.9). A total of 423 (36.6%) patients had a previous cone biopsy. Tumor size (clinical examination) Conclusions In this European cohort, the rate of adjuvant therapy after radical hysterectomy is higher than for most similar patients reported in the literature. The majority of centers were already following the European recommendations even 5 years prior to the ESGO quality indicator implementations.
- 1 August 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (8) , 1188-1189
Intra-operative radiation therapy after a total lateral extended infralevator exenteration for recurrent cervical cancer
- 1 August 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (8) , 1188-1189
Intra-operative radiation therapy after a total lateral extended infralevator exenteration for recurrent cervical cancer
- 1 May 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (5) , 793-794
Thoracic anatomical landmarks and uniportal VATS cardiophrenic lymph node resection in advanced ovarian cancer
- 1 May 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (5) , 793-794
Thoracic anatomical landmarks and uniportal VATS cardiophrenic lymph node resection in advanced ovarian cancer
- 1 April 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (4) , 635-636
PleurX indwelling pleural catheter for the treatment of recurrent pleural effusion in advanced ovarian cancer
- 1 April 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (4) , 635-636
PleurX indwelling pleural catheter for the treatment of recurrent pleural effusion in advanced ovarian cancer
- 1 February 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (2) , 300-301
Double identification of sentinel lymph node with indocyanine green and 99m-technetium in vulvar cancer and V–Y flap for vulvar reconstruction
- 1 February 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (2) , 300-301
Double identification of sentinel lymph node with indocyanine green and 99m-technetium in vulvar cancer and V–Y flap for vulvar reconstruction